A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 12, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Hepatic InsufficiencyNeoplasms
Interventions
DRUG

Onureg

Specified dose on specified days

Trial Locations (18)

1426

Local Institution - 0012, Buenos Aires

1629

Local Institution - 0011, Pilar

20246

Local Institution - 0074, Hamburg

22903

Local Institution - 9003, Charlottesville

31008

Local Institution - 0015, Pamplona

37007

Local Institution - 0078, Salamanca

44106

Local Institution, Cleveland

48202

Local Institution - 0069, Detroit

52242

Local Institution - 0083, Iowa City

86156

Local Institution - 0076, Augsburg

110131

Local Institution - 0085, Bogotá

111151

Local Institution - 0084, Bogota

681017

Local Institution - 0086, Piedecuesta

C1199ABB

Local Institution - 0010, ABB

C1118AAT

Local Institution - 0014, Buenos Aires

06120

Local Institution - 0075, Halle

08916

Local Institution - 0018, Badalona

08035

Local Institution - 0017, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY